Intercept Pharmaceuticals EPS beats by $0.06, misses on revenue

|About: Intercept Pharmaceuticals (ICPT)|By:, SA News Editor

Intercept Pharmaceuticals (ICPT): Q4 EPS of -$0.64 beats by $0.06.

Revenue of $405K (flat Y/Y) misses by $485K.

Says it expects to be able to fund operations into Q3 2015 based upon currently expected level of program commitment and expected operating expenditures.

Shares -13.6% AH.